Vancomycin is a glycopeptide antibiotic. Approved by FDA on January 29, 2018. Active against most strains of the microorganisms, both in vitro and in clinical infections. The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function. Vancomycin is approximately 55% serum protein-bound. It has a rapid onset of action. Effective against severe Gram +Ve Infection. Drug of choice for serious MRSA Infection. Susceptible to B- lactam & macrolide antibiotics.
MODE OF ACTION:
Vancomycin exerts its bactericidal effect by inhibiting the polymerization of peptidoglycans in the bacterial cell wall. Vancomycin binds to d-alanyl d-alanine, which inhibits peptidoglycan synthase and the p-phospholipid carrier, thereby preventing the synthesis and polymerization of NAM and NAG within the peptidoglycan layer. Ultimately causes leakage of intracellular components, resulting in bacterial cell death.
- Infection of Lungs and Skin
- Septicemia caused by MRSA
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.